Edition:
United States

EyeGate Pharmaceuticals Inc (EYEG.OQ)

EYEG.OQ on NASDAQ Stock Exchange Capital Market

0.35USD
4:00pm EDT
Change (% chg)

$-0.03 (-7.67%)
Prev Close
$0.38
Open
$0.36
Day's High
$0.38
Day's Low
$0.33
Volume
93,574
Avg. Vol
127,756
52-wk High
$1.38
52-wk Low
$0.29

Chart for

About

Eyegate Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company's lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone... (more)

Overall

Beta: 3.27
Market Cap(Mil.): $16.85
Shares Outstanding(Mil.): 43.44
Dividend: --
Yield (%): --

Financials

  EYEG.OQ Industry Sector
P/E (TTM): -- 29.75 32.14
EPS (TTM): -0.62 -- --
ROI: -109.00 13.18 12.83
ROE: -133.92 15.14 14.95

BRIEF-EyeGate Submits Investigational Device Exemption Amendment For Ocular Bandage Gel

* EYEGATE ADDRESSES MAJORITY OF FDA’S ACTION ITEMS WITH SUBMISSION OF INVESTIGATIONAL DEVICE EXEMPTION AMENDMENT FOR OCULAR BANDAGE GEL

May 22 2018

BRIEF-EyeGate Pharmaceuticals Says On May 15, Board Increased Size To Eight From Seven

* EYEGATE PHARMACEUTICALS INC - ON MAY 15, BOARD INCREASED SIZE OF BOARD FROM SEVEN DIRECTORS TO EIGHT DIRECTORS - SEC FILING Source http://bit.ly/2KuxceA Further company coverage:

May 16 2018

BRIEF-Eyegate Pharmaceuticals Posts Q1 Revenue Of $1.096 Million

* EYEGATE PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

May 11 2018

Earnings vs. Estimates